Disney Makes Case for Being Legitimate Death Star in US Box Office
Disney topped the weekend box office for the second straight time, notching a cool $72 million in North American ticket sales.
All Work
Chris Lange
The Worst Performing Retailers of 2019
24/7 Wall St. has put together a list of retailers that have suffered the most in 2019.
Why This Uriniary Tract Infection Trial Could Be Huge
Iterum Therapeutics shares more than doubled on Friday after the firm announced that it had completed the enrollment of its late-stage clinical trial in uncomplicated urinary tract infections.
Is This a Buying Opportunity for Cannabis ETFs Going Into 2020?
Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation, there is added risk that has to be considered.
Will a Record National Returns Day Hurt Amazon?
In a note Thursday, UPS said that it forecasts a record National Returns Day, with 1.9 million returns expected, up 26% from last year. This will be the seventh consecutive record National Returns Day…
Why This China Deal Is Huge for Pintec
Pintec Technology shares nearly doubled on Friday after the firm announced an agreement with China Unicom to expand its offerings.
Why This Osteoarthritis Treatment Is Making Waves
Flexion Therapeutics shares popped on Friday after the company announced that the FDA has approved a supplemental New Drug Application to update the product label for Zilretta for the treatment of osteoarthritis knee pain.
The Top Healthy Living ETFs of 2019
Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking greatly increase one’s odds of living a long and healthy life. With these trends gaining ever more traction, they…
Could This Breast Cancer Study Be the Next Big Thing?
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment.
Why This Cancer Study Is Crushing Spectrum Pharma
Spectrum Pharma shares were halved on Thursday after the firm provided an update on its midstage cancer study some updates on its late-stage programs with the FDA.
Is Semiconductor Short Interest Signaling Further Market Highs?
The December 13 short interest data have been compared with the previous report. Short interest in most of these selected semiconductor stocks decreased.
Big Pharma Short Sellers Get Selective
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Short Sellers Yield on Cannabis Stocks
The December 13 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks decreased.
Major Biotechs See Rising Short Interest
The December 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Will Microbot Medical’s Robotic Surgery System Be a Big Hit?
Microbot Medical shares made a massive gain on Tuesday after the company revealed its Liberty system, which would be the world’s first fully disposable robotic system for use in neurovascular, cardiovascular and peripheral vascular…
Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics
NewLink Genetics shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with Ellipses Pharma.
Auto Sales Could Dip for December
Although retail auto sales are expected to dip for the 2019 year, there could be a silver lining, at least according to a report from J.D. Power.
Why Wedbush Now Has the Street’s Highest Apple Target
Apple is putting the finishing touches on what has been a historic year for the company and will serve as a launching pad for 2020 to be the "year of an iPhone supercycle". Wedbush…
The Top Biopharma Calendar Events to Watch Going Into 2020
Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to watch for going into 2020.
Why This Duchenne Muscular Dystropy Deal Could Be Huge
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.